Research output per year
Research output per year
Project Details
Abstract
Conclusions: We show that infliximab is one of the adoptive therapies in refractory KD patients. Different behaviors of pro-inflammatory cytokines and DAMP molecules and VEGF after infliximab treatment suggest that infliximab is effective for suppression of cytokine-mediated inflammation, but could not completely block local vasculitis.
| Status | Finished |
|---|---|
| Effective start/end date | 2008/01/01 → 2009/12/31 |
Funding
- Japan Society for the Promotion of Science: ¥4,160,000.00
Keywords
- 川崎病
- 冠動脈病変(CAL)
- 免疫グロブリン大量療法(IVIG)
- Pathogen Associated Molecular Pattern(PAMP)
- インフリキシマブ
- 血管炎
- サイトカイン
-
Absence of parvoviral genomes in endothelial cells of Kawasaki disease patients with coronary artery lesions
Bowles, N. E., Hirono, K., Yu, X. & Ichida, F., 2009/04, In: Pediatric Infectious Disease Journal. 28, 4, p. 345 1 p.Research output: Contribution to journal › Letter › peer-review
Open Access8 Scopus citations -
Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory kawasaki disease
Hirono, K., Kemmotsu, Y., Wittkowski, H., Foell, D., Saito, K., Ibuki, K., Watanabe, K., Watanabe, S., Uese, K., Kanegane, H., Origasa, H., Ichida, F., Roth, J., Miyawaki, T. & Saji, T., 2009/06, In: Pediatric Research. 65, 6, p. 696-701 6 p.Research output: Contribution to journal › Article › peer-review
Open Access58 Scopus citations